Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to TAF in Chronic Hepatitis B
NCT03489239Phase 3Active, not recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Nov 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Thomas Jefferson University. Started Nov 2017; status: active, not recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03489239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489239.